Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2012

View Archived Issues

New vaccines for dengue virus presented by Merck & Co.

New diagnostic agents for cancer designed by Bayer Schering Pharma

Roche patents new glucokinase activators for diabetes

Dual PI3K/mTOR inhibitors prove active in glioblastoma cells

Proof-of-concept of a novel enzyme-based drug delivery system

Favorable safety observed for BI-853520 in phase I study

FORMA Therapeutics divulges novel NAmPRTase inhibitors

New Zealand and U.S. researchers present new antimalarial agents

Merck & Co. prepares new agents for hypertension

New bromodomain-containing protein inhibitors disclosed by GlaxoSmithKline

Phase I data presented for PF-04449913 in advanced solid tumors

Rapid antidepressant effects seen for AZD-6765 in patients

Cellceutix updates on Kevetrin trial

Merck begins phase II/III MK-8931 study

Clinical program commences for reformulated muscle relaxant Metaxalone SoluMatrix

Novartis launches Xolair for s.c. injection 75 mg in Japan

Theravectys receives clearance for first human trial of anti-HIV vaccine

Optimer Pharmaceuticals and AstraZeneca collaborate on fidaxomicin

Ryzodeg passes First Committee on Drugs of Pharmaceutical Affairs review in Japan

Galapagos opens GLPG-0634 IND in the U.S.

PharmaEssentia acquires certain rights to KX-01 in Asia

MSD K.K. files for approval of insomnia agent in Japan

Tracleer obtains additional indication approval in Japan

Canadian authorities assessing reimbursement for newly approved cystic fibrosis treatment Kalydeco

Synthetic Biologics acquires beta-lactamase compounds from Prev AbR

Altravax receives grant from NIH to develop vaccines for HIV/AIDS

Horizon Pharma launches novel prednisone formulation in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...